Compare Cytokinetics Inc (CYTK) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| CYTK | XLP | |
|---|---|---|
Market Cap | $8.62B | $13.50B |
Volume | 2,594,626 | 14,599,953 |
Sector | Health | — |
52-Week High | $87.26 | $90.00 |
52-Week Low | $54.76 | $75.61 |
Typical Hold Time | 19 Days | 72 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
XLP trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong relative performance against discretionary peers, gaining 6.6% year-to-date while XLY declined over 7%. Analyst consensus is unanimously bullish with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peer funds.
The outlook remains positive given XLP's defensive positioning in consumer staples, low 0.08% expense ratio, and strong technical momentum. However, risks include sensitivity to interest rate movements and potential consumer spending slowdown. The ETF's proximity to resistance at $84 suggests near-term consolidation may precede further upside if bullish momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
